Download PDF
Psychiatrie und Psychotherapie up2date 2011; 5(02): 97-111
DOI: 10.1055/s-0030-1265958
Schizophrenien und andere psychotische Störungen

Langzeitbehandlung der Schizophrenie

David Zilles
,
Oliver Gruber
› Further Information
    Permissions and Reprints All articles of this category
Kernaussagen

Allein aufgrund der Komplexität des Krankheitsbildes mit seinen verschiedenen Symptomebenen kann es keine einheitliche Therapie der Schizophrenie geben.

Umso wichtiger ist jedoch die Berücksichtigung aller zur Verfügung stehenden Therapieoptionen mit dem Ziel, einen individuell möglichst guten Krankheitsverlauf zu erreichen.

Eine Reduktion der Positivsymptomatik ist dabei ein zwar wichtiger, aber nicht alleine ausreichender Schritt.

Insbesondere aufgrund des starken Einflusses von Kognition und Negativsymptomatik auf soziales Funktionsniveau und Lebensqualität des Patienten müssen auch diese Symptombereiche in der Therapie Beachtung finden.

Die oben genannten Therapieoptionen stellen dabei zumindest Möglichkeiten für eine individuelle, symptomzentrierte Behandlung dar. Eine breitere Verfügbarkeit bereits etablierter und nachweislich wirksamer Therapien wäre dabei wünschenswert.



Publication History

Publication Date:
09 February 2011 (online)

© Georg Thieme Verlag KG Stuttgart · New York

 

  • Literatur

  • Wobrock T, Gruber O. Pharmakotherapie der Schizophrenie – Leitliniengerecht und individuell.. Psychoneuro 2008; 34: 184-190
    Article in Thieme ConnectGoogle Scholar
  • Arato M, O’Connor R, Meltzer HY. ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg / day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study.. Int Clin Psychopharmacol 2002; 17: 207-215
    CrossrefPubMedGoogle Scholar
  • Beasley CM, Sutton VK, Hamilton SH. et al Olanzapine Relapse Prevention Study Group. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse.. J Clin Psychopharmacol 2003; 23: 582-594
    CrossrefPubMedGoogle Scholar
  • Pigott TA, Carson WH, Saha AR. et al Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.. J Clin Psychiatry 2003; 64: 1048-1056
    CrossrefPubMedGoogle Scholar
  • Leucht S, Barnes TR, Kissling W. et al Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.. Am J Psychiatry 2003; 160: 1209-1222
    CrossrefPubMedGoogle Scholar
  • Schooler N, Rabinowitz J, Davidson M. et al Early Psychosis Global Working Group. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.. Am J Psychiatry 2005; 162: 947-953
    CrossrefPubMedGoogle Scholar
  • Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics.. CNS Drugs 2002; 16: 473-484
    CrossrefPubMedGoogle Scholar
  • Gaebel W, Riesbeck M, Wölwer W. et al German Study Group on First-Episode Schizophrenia. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.. J Clin Psychiatry 2007; 68: 1763-1774
    CrossrefPubMedGoogle Scholar
  • Buchanan RW, Kreyenbuhl J, Kelly DL. et al Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.. Schizophr Bull 2010; 36: 71-93
    CrossrefPubMedGoogle Scholar
  • Lieberman JA, Stroup TS, McEvoy JP. et al Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.. N Engl J Med 2005; 353: 1209-1223
    CrossrefPubMedGoogle Scholar
  • McEvoy JP, Lieberman JA, Stroup TS. et al Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.. Am J Psychiatry 2006; 163: 600-610
    CrossrefPubMedGoogle Scholar
  • Leucht S, Corves C, Arbter D. et al Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.. Lancet 2009; 373: 31-41
    CrossrefPubMedGoogle Scholar
  • Rummel C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia.. Cochrane Database Syst Rev 2006; 3: CD005581
    Google Scholar
  • Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.. Biol Psychiatry 2004; 55: 1013-1022
    CrossrefPubMedGoogle Scholar
  • Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.. Am J Psychiatry 2001; 158: 176-184
    CrossrefPubMedGoogle Scholar
  • Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.. Am J Psychiatry 2004; 161: 414-425
    CrossrefPubMedGoogle Scholar
  • Gaebel W, Jänner M, Frommann N. et al First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies.. Schizophr Res 2002; 53: 145-159
    CrossrefPubMedGoogle Scholar
  • Falkai P, Wobrock T, Lieberman J. et al WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.. World J Biol Psychiatry 2006; 7: 5-40
    CrossrefPubMedGoogle Scholar
  • Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia.. Cochrane Database Syst Rev 2005; 2: CD000076
    Google Scholar
  • Mobascher A, Arends M, Eschweiler GW. et al [Biological correlates of prefrontal activating and temporoparietal inhibiting treatment with repetitive transcranial magnetic stimulation (rTMS)].. Fortschr Neurol Psychiatr 2009; 77: 432-443
    PubMedGoogle Scholar
  • Slotema CW, Blom JD, Hoek HW. et al Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? a meta-analysis of the efficacy of rTMS in psychiatric disorders.. J Clin Psychiatry 2010; 71: 873-884
    CrossrefPubMedGoogle Scholar
  • Dlabac-de Lange JJ, Knegtering R, Aleman A. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis.. J Clin Psychiatry 2010; 71: 411-418
    CrossrefPubMedGoogle Scholar
  • Schaub A. Kognitiv-verhaltenstherapeutische Interventionen bei schizophrenen und verwandten Störungen.. In: Leibing E, Hiller W, Sulz SKD. Hrsg Lehrbuch der Psychotherapie, Band 3 Verhaltenstherapie.. München: CIP-Medien; 2003: 209-216
    Google Scholar
  • Wiedemann G, Klingberg S. Psychotherapy of positive symptoms in the treatment of patients with schizophrenia psychosis.. Nervenarzt 2003; 74: 76-84
    CrossrefPubMedGoogle Scholar
  • DGPPN. S3-Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1: Behandlungsleitlinie Schizophrenie.. Darmstadt: Steinkopff; 2006
    Google Scholar
  • Jones C, Cormac I, Silveira da Mota Neto JI. et al Cognitive behaviour therapy for schizophrenia.. Cochrane Database Syst Rev 2004; 4: CD000524
    Google Scholar
  • Wykes T, Steel C, Everitt B. et al Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor.. Schizophr Bull 2008; 34: 523-537
    CrossrefPubMedGoogle Scholar
  • Lynch D, Laws KR, McKenna PJ. Cognitive behavioural therapy for major psychiatric disorder: does it really work? A meta-analytical review of well-controlled trials.. Psychol Med 2010; 40: 9-24
    CrossrefPubMedGoogle Scholar
  • Bäuml J, Pitschel-Walz G. Psychoedukation bei schizophrenen Erkrankungen.. Stuttgart: Schattauer; 2003
    Google Scholar
  • Pekkala E, Merinder L. Psychoeducation for schizophrenia.. Cochrane Database Syst Rev 2002; 2: CD002831
    Google Scholar
  • Lincoln TM, Wilhelm K, Nestoriuc Y. Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis.. Schizophr Res 2007; 96: 232-245
    CrossrefPubMedGoogle Scholar
  • Pharoah F, Mari J, Rathbone J. et al Family intervention for schizophrenia.. Cochrane Database Syst Rev 2006; 4: CD000088
    Google Scholar
  • Zilles D, Gruber O. Kognitive Störungen bei schizophrenen Patienten: Ihre Relevanz in Wissenschaft und klinischer Praxis.. Psychoneuro 2008; 34: 191-199
    Article in Thieme ConnectGoogle Scholar
  • Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS.. Schizophr Res 2004; 72: 41-51
    CrossrefPubMedGoogle Scholar
  • McGurk SR, Twamley EW, Sitzer DI. et al A meta-analysis of cognitive remediation in schizophrenia.. Am J Psychiatry 2007; 164: 1791-1802
    CrossrefPubMedGoogle Scholar
  • Kurtz MM, Mueser KT. A meta-analysis of controlled research on social skills training for schizophrenia.. J Consult Clin Psychol 2008; 76: 491-504
    CrossrefPubMedGoogle Scholar
  • Weinmann S, Puschner B, Becker T. Innovative structuring in German care for schizophrenics.. Nervenarzt 2009; 80: 31, 33–34, 36–39
    Google Scholar
  • Crowther R, Marshall M, Bond G. et al Vocational rehabilitation for people with severe mental illness.. Cochrane Database Syst Rev 2001; 2: CD003080
    Google Scholar
  • Dixon LB, Dickerson F, Bellack AS. Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements.. Schizophr Bull 2010; 36: 48-70
    CrossrefPubMedGoogle Scholar